Bespoke Extracts (BSPK) Share-based Compensation (2011 - 2025)
Bespoke Extracts (BSPK) reported Share-based Compensation of $2960.0 for Q1 2025, down 94.13% on a YoY basis from $50418.0 in Q1 2024, and up 110.56% sequentially from -$28028.0 in Q4 2024.
Bespoke Extracts (BSPK) Share-based Compensation (2011 - 2025) Analysis & Trends
Bespoke Extracts (BSPK) has 12 years of Share-based Compensation data on file, last reported at $2960.0 in Q1 2025.
- For the quarter ending Q1 2025, Share-based Compensation fell 94.13% year-over-year to $2960.0; the trailing twelve-month figure through Sep 2025 stood at -$25068.0 (down 109.9% YoY), and the FY2024 full-year result was $197523.0, down 48.07% from the prior year.
- Share-based Compensation advanced to $2960.0 in Q1 2025, from -$28028.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $1.3 million in Q4 2022 to a low of -$74000.0 in Q1 2021.
- A 5-year average of $225847.1 and a median of $92344.0 in 2023 frame the typical range for Share-based Compensation.
- Peak annual rise in Share-based Compensation reached 38.51% in 2024, while the deepest fall reached 128.51% in 2024.
- Tracing BSPK's Share-based Compensation over 5 years: stood at $35500.0 in 2021, then soared by 3588.65% to $1.3 million in 2022, then slumped by 92.49% to $98303.0 in 2023, then sank by 128.51% to -$28028.0 in 2024, then surged by 110.56% to $2960.0 in 2025.
- Business Quant data shows BSPK's Share-based Compensation at $2960.0 in Q1 2025, -$28028.0 in Q4 2024, and $47679.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 43.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 25.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 125.69 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 58.30 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 56.50 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 55.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.00 Mn |
| 10 | Bespoke Extracts | 1.12 Mn | 1.11 Mn | 234,175.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 2,960.00 |
| Mar 31, 2025 | 2,960.00 |
| Dec 31, 2024 | -28,028.00 |
| Dec 31, 2024 | -28,028.00 |
| Sep 30, 2024 | 47,679.00 |
| Sep 30, 2024 | 47,679.00 |
| Jun 30, 2024 | 56,784.00 |
| Jun 30, 2024 | 56,784.00 |
| Mar 31, 2024 | 50,418.00 |
| Mar 31, 2024 | 50,418.00 |
| Dec 31, 2023 | 98,303.00 |
| Dec 31, 2023 | 98,303.00 |
| Sep 30, 2023 | 97,303.00 |
| Sep 30, 2023 | 97,303.00 |
| Jun 30, 2023 | 92,344.00 |
| Jun 30, 2023 | 92,344.00 |
| Mar 31, 2023 | 92,432.00 |
| Mar 31, 2023 | 92,432.00 |
| Dec 31, 2022 | 1.31 Mn |
| Dec 31, 2022 | 1.31 Mn |